No Data
US Stock MarketDetailed Quotes
BNTC Benitec Biopharma
Watchlist
0.241
+0.011+4.83% Close 05/31 16:00 ET
0.253+0.012+4.94%
Post 19:59 ET
0.247High0.220Low286.60KVolume
0.240Open0.230Pre Close67.16KTurnover1.17%Turnover RatioLossP/E (TTM)6.75MMarket Cap2.10052wk HighLossP/E (Static)27.98MShares0.13152wk Low1.44P/B5.89MFloat Cap231.761Historical High--Dividend TTM24.42MShs Float0.131Historical Low--Div YieldTTM11.87%Amplitude0.234Avg Price1Lot Size
Post-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Company
Benitec Biopharma, Inc. is a development-stage biotechnology company, which engages in the advancement of novel genetic medicines. The firms' proprietary platforms include DNA-directed RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitates sustained silencing of disease-causing genes following a single administration. It is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy, and Chronic Hepatitis B. The company was founded on November 22, 2019 and is headquartered in Hayward, CA.
Revenue Breakdown
Business
Unit:USD
NameYOYOperating income%
Licensing revenue--73K100.00%
News
Express News | Benitec Biopharma Price Target Maintained With a $4.00/Share by JMP Securities
JMP Securities Reiterates Market Outperform on Benitec Biopharma, Maintains $4 Price Target
JMP Securities analyst Silvan Tuerkcan reiterates Benitec Biopharma (NASDAQ:BNTC) with a Market Outperform and maintains $4 price target.
JMP Securities Remains a Buy on Benitec Biopharma (BNTC)
